About Malvyn
Malvyn is a Healthcare company. Malvyn focuses on specialty pharmaceuticals, including DMARDs, pain management, and nutritionals. Its Indian entity Malvyn Pharmaceuticals Private Limited reported revenue of ₹76 Lakh. Malvyn offers products and services including DMARDs and Pain Management Medicines. Its focus areas include Medical Supplies, Therapeutic Solutions, Nutritional Support and Pharmaceuticals.
Company details
Malvyn Pharmaceuticals Pvt. Ltd. is recognized as a drug house specializing in the marketing of specialty products, where annual general meetings are conducted to present reports and insights from the CEO and directors. DMARDs are utilized to manage rheumatoid arthritis by slowing joint damage, while a range of pain management medicines is offered to improve quality of life for those with pain conditions. Nutritional products are promoted to address lifestyle disorders through better eating habits across populations. Contact is facilitated via specified email and address in India, ensuring support for product-related queries. All trademarks are acknowledged as property of their owners, with operations centered on healthcare advancements.
- SectorsHealthcare
- Email••••••••
- Legal Name Malvyn Pharmaceuticals Pvt. Ltd
- Date of Incorporation 07 Apr, 2016
- Jurisdiction Allahabad, Uttar Pradesh, India
- Indian entity revenue₹76 Lakh
FY 2024 · -3% YoY
- Indian entity net loss-₹4.6 Lakh
FY 2024 · -6% margin
- Indian entity EBITDA-₹4.2 Lakh
FY 2024 · -6% margin
Associated legal entities of Malvyn
Malvyn operates through Malvyn Pharmaceuticals Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Malvyn Pharmaceuticals Private Limited CIN U33301UP2016PTC082585 | Active | 07 Apr 2016 | Allahabad, Uttar Pradesh | ₹0.8 Cr | 3 | View details |
Products & Services of Malvyn
Malvyn offers a comprehensive portfolio of products and services, including DMARDs and Pain Management Medicines.
DMARDs are employed for slowing the progression of joint damage in rheumatoid arthritis, serving as a key element in treatment plans
A variety of pain management medicines is provided to alleviate suffering and enhance the quality of life for individuals experiencing chronic or acute pain
Board of directors of Malvyn Pharmaceuticals Private Limited (Malvyn)
Malvyn Pharmaceuticals Private Limited is the primary company behind Malvyn. The board of Malvyn Pharmaceuticals Private Limited currently have 3 directors; the longest-serving is Suresh Chandra Mishra, appointed in 2016.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Suresh Chandra Mishra DIN 07479526 | Director | 07 Apr 2016 | 10 yrs 6 mo | Malvyn Pharmaceuticals Private Limited |
| Harsh Rajprakash Mishra DIN 08523961 | Additional Director | 13 Aug 2019 | 7 yrs 2 mo | Malvyn Pharmaceuticals Private Limited |
| Rajprakash Srinarayan Mishra DIN 07479515 | Additional Director | 10 Mar 2022 | 4 yrs 7 mo | Malvyn Pharmaceuticals Private Limited |
Financials of Malvyn
Figures of Malvyn Pharmaceuticals Private Limited, the primary company behind Malvyn, for FY 2024. Revenue was ₹76 Lakh (-3% year on year). Net loss was -₹4.6 Lakh (-6% margin). EBITDA was -₹4.2 Lakh (-6% margin). Revenue has grown at a compounded annual rate of +11% over three years and +4% over five years.
- ₹76 LakhRevenue · FY 2024 · -3% YoY
- -₹4.6 LakhNet loss · -6% margin
- -₹4.2 LakhEBITDA · -6% margin
- ₹5 LakhPaid-up capital
- +11%Revenue CAGR, 3 years
- +4%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Malvyn Pharmaceuticals Private Limited are on its company page.
Detailed financial statements for Malvyn
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Malvyn
The primary company behind Malvyn, Malvyn Pharmaceuticals Private Limited, reported revenue of ₹76 Lakh for FY 2024, down 3% year on year.
Malvyn Pharmaceuticals Pvt. Ltd. is recognized as a drug house specializing in the marketing of specialty products, where annual general meetings are conducted to present reports and insights from the CEO and directors. DMARDs are utilized to manage rheumatoid arthritis by slowing joint damage, while a range of pain management medicines is offered to improve quality of life for those with pain conditions. Nutritional products are promoted to address lifestyle disorders through better eating habits across populations. Contact is facilitated via specified email and address in India, ensuring support for product-related queries. All trademarks are acknowledged as property of their owners, with operations centered on healthcare advancements.
Malvyn offers DMARDs and Pain Management Medicines.
Malvyn operates through Malvyn Pharmaceuticals Private Limited.
The legal entities of Malvyn currently have 3 directors, including Suresh Chandra Mishra, Harsh Rajprakash Mishra, Rajprakash Srinarayan Mishra.